Atezolizumab (1200 mg every three weeks)

BIOLOGICAL2 trials

Sponsors

Darell Bigner, Huashan Hospital

Conditions

Malignant GliomaRecurrent Glioblastoma

Early Phase 1

Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma

RecruitingNCT07538128

Huashan HospitalRecurrent Glioblastoma

Start: 2025-01-09End: 2027-02-28Target: 10Updated: 2026-04-20

Phase 1

D2C7-IT With Atezolizumab for Recurrent Gliomas

Active, not recruitingNCT04160494

Darell BignerMalignant Glioma

Start: 2020-02-25End: 2027-12-31Target: 18Updated: 2025-05-11